Free Shipping on orders over $150
1

Retatrutide

Triple Agonist Peptide / GLP-1-GIP-Glucagon Origin

Retatrutide is a synthetic peptide engineered as a triple receptor agonist, and it carries an indexed body of research literature spanning 153 PubMed-cataloged studies, including 34 clinical trials.

Price range: $99.00 through $225.00

Retatrutide is a triple agonist targeting GLP-1, GIP, AND glucagon receptors, making it the most mechanistically complex metabolic peptide currently in research. The addition of glucagon

Premium Subscribers only. This compound is part of the restricted catalog. Become a Premium subscriber to purchase.

Certificates of Analysis

Independently tested by Horizon Analytical. Tap to open the full report.

🧪Purity Report
99.42% · Lot LL-2117436-POPEN ↗🛡Endotoxin Report
Lot LL-2117436-EOPEN ↗
SKU: LL-RETA Category:

PubMed Literature Index

153

studies indexed in the public literature

Q2 2026 · view PubMed search ↗

96
Human
103
Animal
34
Clinical Trials
0
EU Trials

Overview

In the literature, retatrutide is described as a triple receptor agonist, the first peptide reported to simultaneously activate GLP-1R, GIPR, and the glucagon receptor (GCGR). Studies describe glucagon receptor agonism as adding a third proposed metabolic axis, distinct from GLP-1 and GIP activity alone, involving hepatic fat mobilization, thermogenesis, and energy expenditure. Phase 2 trial data cited in the literature report body weight reduction of up to 24.2 percent at 48 weeks, with Phase 3 trials described as ongoing.

Chemical & Molecular Properties

CAS2381089-83-2
FormulaC221H342N46O68
Mol. Weight4731 g/mol
PubChem CID171390338

Key Areas of Research Interest

  • Investigated in the context of combined GLP-1, GIP, and glucagon receptor agonism
  • Investigated in the context of hepatic fat mobilization
  • Investigated in the context of thermogenesis and energy expenditure
  • Investigated in the context of body weight change across Phase 2 clinical trials
  • Investigated in the context of multi-receptor incretin and glucagon pathway pharmacology

FAQ

What is Retatrutide commonly researched for?

Retatrutide is studied in the research literature for its proposed triple agonist activity at the GLP-1, GIP, and glucagon receptors, including investigation of hepatic fat mobilization, thermogenesis, and energy expenditure pathways, and has been examined in Phase 2 clinical trials for body weight change.

Is Retatrutide FDA-approved?

No. Sold for laboratory research use only, not FDA-approved, not for human or veterinary consumption.

How is Retatrutide stored?

Retatrutide is shipped lyophilized and frozen, protected from light, and should be refrigerated after reconstitution for research use.

What purity standard does Legendary Labz hold Retatrutide to?

Every lot of Retatrutide is third-party tested to verify purity and identity before release for research use.

Is a Certificate of Analysis available for Retatrutide?

Yes. A Certificate of Analysis is published for Retatrutide per lot, including endotoxin testing results.

Materials referenced on this page are intended for laboratory research purposes. No claims regarding therapeutic efficacy are made or implied. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.

Description

Overview

Retatrutide is a triple agonist targeting GLP-1, GIP, AND glucagon receptors, making it the most mechanistically complex metabolic peptide currently in research. The addition of glucagon agonism introduces direct thermogenic effects (increases energy expenditure) and enhanced lipolysis on top of the appetite suppression and insulin regulation of dual agonists. Phase 2 trials showed up to 24.2% weight loss at 48 weeks, exceeding tirzepatide in preliminary comparisons.

Structure & Chemistry

  • Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
  • Category: METABOLIC / WEIGHT MANAGEMENT
  • Molecular size: 4,731.3 Da (39-amino-acid peptide)

Regulatory & Research Status

  • FDA: Not approved. In Phase 3 clinical trials (TRIUMPH program). Available through research/compounding only in the US pending approval.
  • WADA: Prohibited S2 (Peptide Hormones, Growth Factors), banned in and out of competition.
  • Evidence: Phase 2 data (n=338, Jastreboff et al. NEJM 2023) showed 24.2% weight loss at 48 weeks. Phase 3 outcomes pending.

Specifications

Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category METABOLIC / WEIGHT MANAGEMENT
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Additional information

Size

10mg, 30mg

Certificates of Analysis

Independently tested by Horizon Analytical. Tap to open the full report.

🧪Purity Report
99.42% · Lot LL-2117436-POPEN ↗🛡Endotoxin Report
Lot LL-2117436-EOPEN ↗

Reviews

There are no reviews yet.

Be the first to review “Retatrutide”

Your email address will not be published. Required fields are marked *

Overview

Retatrutide is a triple agonist targeting GLP-1, GIP, AND glucagon receptors, making it the most mechanistically complex metabolic peptide currently in research. The addition of glucagon agonism introduces direct thermogenic effects (increases energy expenditure) and enhanced lipolysis on top of the appetite suppression and insulin regulation of dual agonists. Phase 2 trials showed up to 24.2% weight loss at 48 weeks, exceeding tirzepatide in preliminary comparisons.

Structure & Chemistry

  • Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
  • Category: METABOLIC / WEIGHT MANAGEMENT
  • Molecular size: 4,731.3 Da (39-amino-acid peptide)

Regulatory & Research Status

  • FDA: Not approved. In Phase 3 clinical trials (TRIUMPH program). Available through research/compounding only in the US pending approval.
  • WADA: Prohibited S2 (Peptide Hormones, Growth Factors), banned in and out of competition.
  • Evidence: Phase 2 data (n=338, Jastreboff et al. NEJM 2023) showed 24.2% weight loss at 48 weeks. Phase 3 outcomes pending.

Specifications

Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category METABOLIC / WEIGHT MANAGEMENT
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Related Research

Related products